Appropriateness of Crohn’s Disease Therapy in Gastroenterological Rehabilitation

Abstract

Background/Aims: The treatment criteria developed by the European Panel on the Appropriateness of Crohn’s Disease (CD) Therapy (EPACT) have not been applied to rehabilitation. Thus, we retrospectively evaluated appropriateness of treatments during CD rehabilitation using the EPACT website. Methods: We included our 1-year inpatient rehabilitation patients that had been assigned the International Classification of Disease Code for CD. The appropriateness of treatment was assessed in CD categories exhibiting frequent treatment changes. Treatment plans were compared to EPACT recommendations. Results: Charts of 337 proven CD patients (median age 42 [range 17–65] years, 250 women, median Crohn’s Disease Activity Index 140 [range –3 to 427] units) were assigned to EPACT categories. The categories ‘steroid-dependent’ and ‘steroid-refractory’ exhibited frequent treatment changes. In these 59 patients, 16 treatments (13 azathioprine, 1 methotrexate, 2 infliximab) were rated as appropriate. One certolizumab treatment was uncertain. 22 treatments with azathioprine were inappropriate (21 due to underdosing), and 93 treatments (30 mesalamine, 59 steroid, 4 budesonide) were not rated. The number of differences between treatment plans and EPACT recommendations decreased from 45 to 25 in both CD categories (p < 0.0001). Conclusions: We introduce the EPACT website as a practical advance towards an optimal therapy in rehabilitants with steroid-dependent or -refractory CD.

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

“…Notwithstanding their reduced cost, these drugs can generate several side effects. Moreover, these therapies do not achieve clinical remission and they can lead to the onset of other conditions such as renal impairment [ 39 , 49 , 50 ].…”

The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies

“…60,61 However, these treatments present a number of inconvenient side effects and scarce guarantees of clinical remission. 62 This is true particularly of steroids and for this reason several attempts have been carried out in order to develop safer and more effective therapeutic options. Therefore an effective treatment should include an immune modulator capable of controlling inflammation without leading to exacerbated immunosuppression.…”